Navigation Links
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
Date:11/28/2008

ieved to potentiate the activity of these chemicals in the central nervous system (brain and spinal cord). While the exact mechanism of action of Duloxetine is unknown, scientists believe its effects on depression and anxiety symptoms, as well as its effect on pain perception, may be due to increasing the activity of serotonin and norepinephrine in the central nervous system.

Duloxetine is approved in the United States for the acute and maintenance treatment of major depressive disorder, the acute treatment of generalized anxiety disorder, and the management of diabetic peripheral neuropathic pain and fibromyalgia in adults age 18 years and older. Duloxetine is not approved for use in pediatric patients.

Important Safety Information

Duloxetine is approved to treat major depressive disorder and generalized anxiety disorder, and to manage diabetic peripheral neuropathic pain and fibromyalgia. Antidepressants can increase suicidal thoughts and behaviors in children, adolescents, and young adults. Patients should call their doctor right away if they experience new or worsening depression symptoms, unusual changes in behavior, or thoughts of suicide. Be especially observant within the first few months of treatment or after a change in dose. Duloxetine is approved only for adults 18 and over.

Duloxetine is not for everyone. Patients should not take Duloxetine if they have recently taken a type of antidepressant called a monoamine oxidase inhibitor (MAOI), are taking Mellaril(R) (thioridazine), or have uncontrolled glaucoma. Patients should speak with their doctor about any medical conditions they may have including kidney problems, glaucoma, or diabetes. Patients should talk to their doctor if they have itching, right upper belly pain, dark urine, yellow skin or eyes, or unexplained flu-like symptoms, which may be signs of liver problems. Severe liver problems, sometimes fatal, have been repor
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
2. Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement
3. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
4. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
5. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
6. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
7. Lilly and TransPharma Medical Announce Licensing and Development Agreement
8. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
9. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
10. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
11. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... SAN DIEGO , Dec. 17, 2014 /PRNewswire/ ... AEX: PHIA) and Volcano Corporation (NASDAQ: VOLC ), ... cardiovascular applications, today announced that they have entered into a ... a tender offer to acquire all of the issued and ... a total equity purchase price of USD 1 billion (approx. ...
(Date:12/17/2014)... With advancements in neurological and functional ... seeing new growth, according to Kalorama Information. Though ... the majority of market volume, newer 3T systems ... are creating opportunities for more sophisticated applications. The medical ... a rate of 4%, with world market revenues ...
(Date:12/17/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... enrollment in its first Phase 2a study, RXI-109-1301.  ... the 1-month findings that were reported in September ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
(Date:12/20/2014)... Parker & Sons, Inc. a focused and ... in contractor services announces reaching a milestone by providing ... of Arizona. Parker and Sons is comprised of a ... make customer service the number one priority. The company ... with one service vehicle and has since grown to ...
(Date:12/19/2014)... Today, Balfleet.com , a leading ... its formal dress promotion. All the old and new ... off. , Balfleet.com is well-known for its high quality ... dresses, cocktail dresses and more. Its formal dresses are ... and they can create an elegant look when paired ...
(Date:12/19/2014)... 20, 2014 Sweetdressy.com , a ... introduced its newest selection of cheap prom dresses for ... popular in the world and clients can buy these ... these prom dresses feature cool cuts and delicate craftsmanship, ... targeting the middle-end market. Discount shipping costs are available ...
(Date:12/19/2014)... FL (PRWEB) December 19, 2014 ... Revitalizing Bedsheets are now available. Celliant, the world’s ... both sheets and pillowcases. , There are a ... proven additional circulation, increased oxygenation and balanced body ... faster healing and pain relief; enhanced athletic performance; ...
(Date:12/19/2014)... Branson, Missouri (PRWEB) December 19, 2014 ... a new official world record -- for the first time ... most prestigious record book, Guinness World Records 2015, listing the ... Steepest Wooden Roller Coaster. In additional awards announced this week, ... to See Christmas Lights in the US,” USA Today’s 10Best ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 3Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Silver Dollar City Nets New Titles: Guinness Book of World Records, Plus CNN Travel, USA Today & Fodor’s Top Places for Christmas Lights 2
... , WEDNESDAY, Aug. 18 (HealthDay News) -- Although it,s long ... produce any insulin after they,ve had the disease for a ... by type 1 diabetes may actually be in a constant ... decades. , This new research stems from a study ...
... for more than 1,800 years reduced the gastrointestinal side ... effects of the cancer treatment, Yale University researchers report. ... four herbs, called PHY906, and is based on a ... treat nausea, vomiting and diarrhea. The study, published August ...
... Goodwin HealthDay Reporter , WEDNESDAY, Aug. 18 (HealthDay ... cigarettes have emerged as one of the most controversial products ... to them, with nearly 45 percent of smokers aged 12 ... Survey on Drug Use and Health. Most black teenaged smokers ...
... (CHICAGO) Neurological and infectious disease experts at Rush University ... treatment of individuals with West Nile fever or suspected central ... Rush is the only site in the Midwest enrolling patients ... called PARADIGM. The new drug treatment for West ...
... health and science communications firm, announced the results of ... children identified with a rare, fatal, and rapid aging ... a Centers for Disease Control national conference on health ... living in 30 countries had been identified with Progeria, ...
... Middle-aged and elderly Swedish women who regularly ate a small ... in a study reported in Circulation: Heart Failure , ... conducted among 31,823 middle-aged and elderly Swedish women, looked at ... ate, compared to their risk for heart failure. The quality ...
Cached Medicine News:Health News:Long-Term Type 1 Diabetes 'Survivors' Give Clues to the Disease 2Health News:Long-Term Type 1 Diabetes 'Survivors' Give Clues to the Disease 3Health News:FDA Mulling Ban on Menthol Cigarettes 2Health News:FDA Mulling Ban on Menthol Cigarettes 3Health News:FDA Mulling Ban on Menthol Cigarettes 4Health News:Study to examine new treatment for West Nile virus 2Health News:Global media campaign finds 'hidden' children with rare, fatal aging disorder 2Health News:Moderate chocolate consumption linked to lower risks of heart failure 2Health News:Moderate chocolate consumption linked to lower risks of heart failure 3
... MOST Options System is designed to ... of the knee or hip to ... provides the potential for restoration of ... the requirements of a rotating hinge ...
... System (OSS) from Biomet Inc. offers ... designed specifically for orthopaedic surgeons and ... in their patients: significant bone loss, ... revision arthroplasties, and multiple hip revision ...
... Surgical Helmet System from DePuy offers a ... system helps meet OSHA recommendations regarding occupational ... creating a new standard for comfort. ... offer unequaled comfort, featuring a lightweight, hose-free, ...
DePuy's Shoe Boots are sealed thermoplastic boots that help provide splash protection from microorganisms, particulate matter and body fluids....
Medicine Products: